Showing 1 - 10 of 265
Between 1960 and 1997, life expectancy at birth of Americans increased approximately 10% - from 69.7 to 76.5 years - and it has been estimated that the value of life extension during this period nearly equaled the gains in tangible consumption. We investigate whether an aggregate health...
Persistent link: https://www.econbiz.de/10013224922
The social value of an innovation is comprised of the value to consumers and the value to innovators. We estimate that for the HIV/AIDS therapies that entered the market from the late 1980's onwards, innovators appropriated only 5% of the social surplus arising from these new technologies....
Persistent link: https://www.econbiz.de/10013234087
Persistent link: https://www.econbiz.de/10013077983
, including pharmaceuticals such as beta-blockers, aspirin, and ace-inhibitors, and invasive procedures, explains up to 50% and 70 …
Persistent link: https://www.econbiz.de/10013232937
Inefficiency in the U.S. health care system has often been characterized as quot;flat of the curvequot; spending providing little or no incremental value. In this paper, we draw on macroeconomic models of diffusion and productivity to better explain the empirical patterns of outcome improvements...
Persistent link: https://www.econbiz.de/10012754821
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10013139118
We estimate the medical cost per life-year gained from increased utilization of HIV drugs by estimating the impact of increased drug utilization on the life expectancy and drug and hospital expenditure of HIV/AIDS patients, using aggregate (U.S. national-level) data for the period 1982-2001. We...
Persistent link: https://www.econbiz.de/10012760746
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by...
Persistent link: https://www.econbiz.de/10013056202
We use data from the Medicare Current Beneficiary Survey (MCBS) to document the medical spending of Americans aged 65 and older. We find that medical expenses more than double between ages 70 and 90 and that they are very concentrated: the top 10% of all spenders are responsible for 52% of...
Persistent link: https://www.econbiz.de/10013021020
This paper examines the effect of antidepressant use on the likelihood of being employed among HIV-positive women receiving highly active antiretroviral therapy (HAART) in the United States from 1994 to 2004. We use instrumental variables to predict antidepressant use independently of outcomes;...
Persistent link: https://www.econbiz.de/10012747942